GLRX2 and ductal breast carcinoma in situ: At the same time, genomic regions containing Glutaredoxin 2 (GLRX2), Laminin Subunit Alpha 2 (LAMA2), and Growth Arrest Specific 5 (GAS5), which are lost at the AT1 and DCIS stages, respectively, were not ranked as super-enhancers in any of the patients or TNBC cell lines.